Mylan and Lupin are gearing up to launch their Nepexto (etanercept) biosimilar in the second half of 2020, after receiving formal European Commission approval for a pan-European marketing authorization for the rival to Pfizer’s Enbrel.
The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in March. (Also see "Mylan And Lupin Get EU Etanercept Nod" - Generics Bulletin, 30 March, 2020